Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 1 / 2 Trials for Docetaxel (DB01248)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02565901Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment